Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03280056 |
Recruitment Status :
Completed
First Posted : September 12, 2017
Results First Posted : February 29, 2024
Last Update Posted : February 29, 2024
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment |
Condition |
Amyotrophic Lateral Sclerosis (ALS) |
Interventions |
Biological: NurOwn® (MSC-NTF cells) Other: Placebo Other: Bone Marrow aspiration |
Enrollment | 196 |
Recruitment Details | The first participant in Study BCT-002-US signed informed consent on 28 August 2017 The last participant visit took place on 29 September 2020. The study was conducted at 6 clinical sites in the USA. A total of 263 participants were screened for the study, and 196 participants (74.5% of participants screened) were randomly assigned (1:1) to treatment with either NurOwn or placebo. |
Pre-assignment Details | The most common reasons that participants did not meet inclusion criteria were failure to meet the SVC inclusion criterion at the Screening Visit or the required pre-treatment decline in ALSFRSR total score at the randomization visit. From the ITT population, 3 participants in the NurOwn group and 4 participants in the placebo group discontinued prior to treatment. |
Arm/Group Title | NurOwn® (MSC-NTF Cells) | Placebo |
---|---|---|
Arm/Group Description |
NurOwn® (MSC-NTF): One course of treatment that includes three separate intrathecal injections of 100-125 x 10'6 cells every 8 weeks NurOwn® (MSC-NTF): Autologous, bone marrow-derived, mesenchymal stem cells secreting neurotrophic factors Bone marrow aspiration |
One course of treatment that includes three separate intrathecal injections of Placebo every 8 weeks Placebo: liquid solution in syringe for injection Bone marrow aspiration |
Period Title: Overall Study | ||
Started | 95 | 94 |
Completed | 71 | 73 |
Not Completed | 24 | 21 |
Reason Not Completed | ||
Withdrawal by Subject | 12 | 14 |
Death | 9 | 2 |
Adverse Event | 1 | 3 |
Lost to Follow-up | 1 | 1 |
Physician Decision | 0 | 1 |
Early Discontinuation | 1 | 0 |
Arm/Group Title | NurOwn® (MSC-NTF Cells) | Placebo | Total | |
---|---|---|---|---|
Arm/Group Description |
NurOwn® (MSC-NTF): One course of treatment that includes three separate intrathecal injections of 100-125 x 10'6 cells every 8 weeks NurOwn® (MSC-NTF): Autologous, bone marrow-derived, mesenchymal stem cells secreting neurotrophic factors Bone marrow aspiration |
One course of treatment that includes three separate intrathecal injections of Placebo every 8 weeks Placebo: liquid solution in syringe for injection Bone marrow aspiration |
Total of all reporting groups | |
Overall Number of Baseline Participants | 95 | 94 | 189 | |
Baseline Analysis Population Description |
Demographic characteristics were balanced between NurOwn and placebo treatment groups with no statistically significant differences at baseline.
|
|||
Age, Categorical
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 95 participants | 94 participants | 189 participants | |
<=18 years | 0 | 0 | 0 | |
Between 18 and 65 years | 95 | 94 | 189 | |
>=65 years | 0 | 0 | 0 | |
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||||
Mean | Number Analyzed | 95 participants | 94 participants | 189 participants |
48.1 (9.71) | 49.1 (8.38) | 48.6 (9.07) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 95 participants | 94 participants | 189 participants | |
Female |
27 28.4%
|
35 37.2%
|
62 32.8%
|
|
Male |
68 71.6%
|
59 62.8%
|
127 67.2%
|
|
Ethnicity (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 95 participants | 94 participants | 189 participants | |
Hispanic or Latino |
5 5.3%
|
3 3.2%
|
8 4.2%
|
|
Not Hispanic or Latino |
90 94.7%
|
91 96.8%
|
181 95.8%
|
|
Unknown or Not Reported |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Race (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 95 participants | 94 participants | 189 participants | |
American Indian or Alaska Native |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Asian |
5 5.3%
|
7 7.4%
|
12 6.3%
|
|
Native Hawaiian or Other Pacific Islander |
0 0.0%
|
1 1.1%
|
1 0.5%
|
|
Black or African American |
3 3.2%
|
3 3.2%
|
6 3.2%
|
|
White |
87 91.6%
|
81 86.2%
|
168 88.9%
|
|
More than one race |
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Unknown or Not Reported |
0 0.0%
|
2 2.1%
|
2 1.1%
|
|
Region of Enrollment
Measure Type: Number Unit of measure: Participants |
||||
United States | Number Analyzed | 95 participants | 94 participants | 189 participants |
95 | 94 | 189 | ||
Baseline Amyotrophic Lateral Sclerosis Functional Rating ScaleScore
[1] Mean (Standard Deviation) Unit of measure: Units on a scale |
||||
Number Analyzed | 95 participants | 94 participants | 189 participants | |
30.3 (6.5) | 31.4 (6.1) | 30.9 (6.3) | ||
[1]
Measure Description: The ALSFRS-R is a quickly administered (10 minutes) ordinal, validated rating scale (ratings 0-4) used to determine participants' assessment of their capability and independence in 12 functional activities. All 12 activities are relevant in ALS. Initial validity was established by documenting that in ALS patients, change in ALSFRS-R scores correlated with change in strength over time, as measured by quantitative neuromuscular strength testing, and with quality of life measures, and predicted survival. The total score of ALSFRS-R ranges from 0-48, with higher score being better.
|
Name/Title: | Chief Medical Officer |
Organization: | Brainstorm Cell Therapeutics |
Phone: | +1-201-488-0460 |
EMail: | ClinicalTrial@brainstorm-cell.com |
Responsible Party: | Brainstorm-Cell Therapeutics |
ClinicalTrials.gov Identifier: | NCT03280056 |
Other Study ID Numbers: |
BCT-002-US |
First Submitted: | August 29, 2017 |
First Posted: | September 12, 2017 |
Results First Submitted: | December 1, 2023 |
Results First Posted: | February 29, 2024 |
Last Update Posted: | February 29, 2024 |